ОбзорГрафикНовостиTraderScreen

Morgan Stanley Knock-Out IPN/  DE000ME0NNG2  /

Stuttgart
08.11.2024  16:59:12 Изменение+0.16 Бид19:19:00 Предложение19:19:00 Базовый актив Цена исполнения Дата истечения Тип опциона
3.87EUR +4.31% 3.79
Величина цены спроса: 400		 -
Величина цены предложения: -		 Ipsen SA 148.2983 EUR 31.12.2078 Put
GlobeNewswire 29.08 Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Li...
GlobeNewswire 13.08 Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Antici...
GlobeNewswire 08.08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 30.07 Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
GlobeNewswire 26.07 GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cho...
GlobeNewswire 26.07 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire 25.07 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire 25.07 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire 11.07 Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire 09.07 ImCheck Appoints Stephan Braun as Chief Medical Officer
GlobeNewswire 04.07 HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refract...
GlobeNewswire 02.07 Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
GlobeNewswire 02.07 Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire 17.06 GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Det...
GlobeNewswire 11.06 Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire 10.06 GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primar...
GlobeNewswire 10.06 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire 10.06 C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
GlobeNewswire 07.06 Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire 06.06 Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswire 05.06 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire 30.05 NH TherAguix receives FDA Fast Track designation
GlobeNewswire 29.05 GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
GlobeNewswire 22.05 GENFIT: May 22, 2024 Combined Shareholders Meeting Results
GlobeNewswire 15.05 Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results